1. In terms of staffing, Renhe also focuses on sales. The 20 18 annual report of Renhe pharmaceutical shows that the total number of employees in the company is 7362, including 4523 salespeople, accounting for more than 62%. Compared with poor research and development, Renhe's more serious and unavoidable problem is that quality control is full of loopholes and has repeatedly been on the "black list".

2. According to the reporter's incomplete statistics, since 20 18, an important subsidiary of Renhe Pharmaceutical has been punished by the regulatory authorities at least 8 times for unqualified drugs. Life is a matter of life. For a pharmaceutical company, the quality and safety of drugs are not enough, which really doesn't make sense. The propaganda to eliminate the font size is almost a "magic medicine." Due to the bombing of brainwashing advertisements for many years, in the eyes of consumers, the "Renhe" brand still represents a reliable and well-known brand in a certain sense. Renhe pharmaceutical is also trying to develop the value of this signboard.

3. The company will launch new products every once in a while, mainly due to the OEM products. On the interactive platform of Shenzhen Stock Exchange, the Secretary of Renhe Pharmaceutical answered questions from investors. OEM itself is understandable, but Renhe Pharmaceutical and its parent company, renhe group, do not strictly control the quality of the supply chain and sales channels, resulting in uneven product quality and word of mouth, and even suspected of false propaganda, which is very problematic.